179 related articles for article (PubMed ID: 22763563)
1. Highly upregulated expression of CD36 and MSR1 in circulating monocytes of patients with acute coronary syndromes.
Piechota M; Banaszewska A; Dudziak J; Slomczynski M; Plewa R
Protein J; 2012 Aug; 31(6):511-8. PubMed ID: 22763563
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes.
Fuhrman B; Koren L; Volkova N; Keidar S; Hayek T; Aviram M
Atherosclerosis; 2002 Sep; 164(1):179-85. PubMed ID: 12119208
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin enhances cellular uptake of oxidized LDL in adipocytes from hypercholesterolemic rabbits.
Zhao SP; Zhang DQ
Clin Chim Acta; 2004 Jan; 339(1-2):189-94. PubMed ID: 14687909
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome.
Barderas MG; Tuñón J; Dardé VM; De la Cuesta F; Jiménez-Nácher JJ; Tarín N; López-Bescós L; Egido J; Vivanco F
Proteomics; 2009 Apr; 9(7):1982-93. PubMed ID: 19294693
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of a scavenger receptor (CD36) in monocytes from subjects with Type 2 diabetes.
Sampson MJ; Davies IR; Braschi S; Ivory K; Hughes DA
Atherosclerosis; 2003 Mar; 167(1):129-34. PubMed ID: 12618277
[TBL] [Abstract][Full Text] [Related]
6. Internalization of modified lipids by CD36 and SR-A leads to hepatic inflammation and lysosomal cholesterol storage in Kupffer cells.
Bieghs V; Verheyen F; van Gorp PJ; Hendrikx T; Wouters K; Lütjohann D; Gijbels MJ; Febbraio M; Binder CJ; Hofker MH; Shiri-Sverdlov R
PLoS One; 2012; 7(3):e34378. PubMed ID: 22470565
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients.
Puccetti L; Sawamura T; Pasqui AL; Pastorelli M; Auteri A; Bruni F
Eur J Clin Invest; 2005 Jan; 35(1):47-51. PubMed ID: 15638819
[TBL] [Abstract][Full Text] [Related]
8. Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36.
Han J; Hajjar DP; Febbraio M; Nicholson AC
J Biol Chem; 1997 Aug; 272(34):21654-9. PubMed ID: 9261189
[TBL] [Abstract][Full Text] [Related]
9. Enzymatically degraded LDL preferentially binds to CD14(high) CD16(+) monocytes and induces foam cell formation mediated only in part by the class B scavenger-receptor CD36.
Kapinsky M; Torzewski M; Büchler C; Duong CQ; Rothe G; Schmitz G
Arterioscler Thromb Vasc Biol; 2001 Jun; 21(6):1004-10. PubMed ID: 11397711
[TBL] [Abstract][Full Text] [Related]
10. Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes.
Mandosi E; Fallarino M; Gatti A; Carnovale A; Rossetti M; Lococo E; Buchetti B; Filetti S; Lenti L; Morano S
J Atheroscler Thromb; 2010 Jun; 17(6):539-45. PubMed ID: 20134099
[TBL] [Abstract][Full Text] [Related]
11. Varenicline enhances oxidized LDL uptake by increasing expression of LOX-1 and CD36 scavenger receptors through α
Kanaoka Y; Koga M; Sugiyama K; Ohishi K; Kataoka Y; Yamauchi A
Toxicology; 2017 Apr; 380():62-71. PubMed ID: 28202387
[TBL] [Abstract][Full Text] [Related]
12. TGF-beta1 downregulates CD36 and scavenger receptor A but upregulates LOX-1 in human macrophages.
Draude G; Lorenz RL
Am J Physiol Heart Circ Physiol; 2000 Apr; 278(4):H1042-8. PubMed ID: 10749696
[TBL] [Abstract][Full Text] [Related]
13. Lipid-induced insulin resistance is associated with increased monocyte expression of scavenger receptor CD36 and internalization of oxidized LDL.
Kashyap SR; Ioachimescu AG; Gornik HL; Gopan T; Davidson MB; Makdissi A; Major J; Febbraio M; Silverstein RL
Obesity (Silver Spring); 2009 Dec; 17(12):2142-8. PubMed ID: 19521352
[TBL] [Abstract][Full Text] [Related]
14. CD36 mRNA expression is increased in CD14+ monocytes of patients with coronary heart disease.
Teupser D; Mueller MA; Koglin J; Wilfert W; Ernst J; von Scheidt W; Steinbeck G; Seidel D; Thiery J
Clin Exp Pharmacol Physiol; 2008 May; 35(5-6):552-6. PubMed ID: 18067591
[TBL] [Abstract][Full Text] [Related]
15. [Non-ST-elevation acute coronary syndrome. Comparison of effects of atorvastatin and rosuvastatin on blood levels of lipids and markers of inflammation].
Kuznetsova MA; Vaulin NA; Masenko VP; Gratsianskiĭ NA
Kardiologiia; 2010; 50(2):21-5. PubMed ID: 20146674
[TBL] [Abstract][Full Text] [Related]
16. Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin.
Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
Arterioscler Thromb Vasc Biol; 2014 Nov; 34(11):2465-72. PubMed ID: 25212234
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome.
Xu ZM; Zhao SP; Li QZ; Nie S; Zhou HN
Clin Chim Acta; 2003 Dec; 338(1-2):17-24. PubMed ID: 14637261
[TBL] [Abstract][Full Text] [Related]
18. Regulation of MSR-1 and CD36 in macrophages by LOX-1 mediated through PPAR-γ.
Dai Y; Su W; Ding Z; Wang X; Mercanti F; Chen M; Raina S; Mehta JL
Biochem Biophys Res Commun; 2013 Feb; 431(3):496-500. PubMed ID: 23333385
[TBL] [Abstract][Full Text] [Related]
19. Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis.
Reiss AB; Wan DW; Anwar K; Merrill JT; Wirkowski PA; Shah N; Cronstein BN; Chan ES; Carsons SE
Exp Biol Med (Maywood); 2009 Mar; 234(3):354-60. PubMed ID: 19144874
[TBL] [Abstract][Full Text] [Related]
20. Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-gamma ligands Putative contribution of Rho GTPases in statin-induced CD36 expression.
Ruiz-Velasco N; Domínguez A; Vega MA
Biochem Pharmacol; 2004 Jan; 67(2):303-13. PubMed ID: 14698043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
